{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:08:46Z","timestamp":1790309326674,"version":"4.1.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0186587","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T18:08:22Z","timestamp":1508868502000},"page":"e0186587","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-813X","authenticated-orcid":true,"given":"Akira","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuumi","family":"Okuzono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tominari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yabuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Okaniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jdermsci.2014.02.002","article-title":"Effects of the immunosuppressant rapamycin on the expression of human \u03b12(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts","volume":"74","author":"Z Tamaki","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","article-title":"Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy","volume":"38","author":"O Distler","year":"2016","journal-title":"Semin Immunopathol"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar4230","article-title":"Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells","volume":"15","author":"AJ Gilbane","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1523-1747.ep12560826","article-title":"Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization","volume":"90","author":"VM K\u00e4h\u00e4ri","year":"1988","journal-title":"J Invest Dermatol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ken405","article-title":"Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis","volume":"48","author":"I Badea","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cyto.2011.04.001","article-title":"Cytokine profiles in localized scleroderma and relationship to clinical features","volume":"55","author":"K Kurzinski","year":"2011","journal-title":"Cytokine"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"LM Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"ref8","first-page":"479","article-title":"Halofuginone down-regulates Smad3 expression and inhibits the TGF\u03b2-induced expression of fibrotic markers in human corneal fibroblasts","volume":"18","author":"EF Nelson","year":"2012","journal-title":"Mol Vis"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.0022-202x.2001.01690.x","article-title":"Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming growth factor-\u03b2-mediated Smad3 activation in fibroblasts","volume":"118","author":"TL McGaha","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0006-2952(96)00427-3","article-title":"Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone","volume":"52","author":"O Halevy","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1083-8791(03)00151-4","article-title":"Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma","volume":"9","author":"M Pines","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"TL Keller","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s13059-014-0511-2","article-title":"A genomic and evolutionary approach reveals non-genetic drug resistance in malaria","volume":"15","author":"JD Herman","year":"2014","journal-title":"Genome Biol"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI106443","article-title":"The relationship between the free pool of proline and collagen content in human liver cirrhosis","volume":"49","author":"D Kershenobich","year":"1970","journal-title":"J Clin Invest"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bbrc.2017.05.064","article-title":"Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with L-proline","volume":"488","author":"R Adachi","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbrc.2017.01.045","article-title":"Prolyl-tRNA synthetase inhibition promotes cell death in SK-MEL-2 cells through GCN2-ATF4 pathway activation","volume":"488","author":"T Arita","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"JC McGrath","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"13","key":"ref18","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP","volume":"172","author":"JC McGrath","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.0959-9673.2004.00377.x","article-title":"Smad3 as a mediator of the fibrotic response","volume":"85","author":"KC Flanders","year":"2004","journal-title":"Int J Exp Pathol"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-\u03b2 signaling in fibrosis","volume":"29","author":"A Biernacka","year":"2011","journal-title":"Growth Factors"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/jmg.40.1.e7","article-title":"The severe form of type I hyperprolinaemia results from homozygous inactivation of the PRODH gene","volume":"40","author":"H Jacquet","year":"2003","journal-title":"J Med Genet"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0006-2952(01)00753-5","article-title":"Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone","volume":"62","author":"M Pines","year":"2001","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/art.10549","article-title":"Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism","volume":"46","author":"TL McGaha","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1096\/fj.14-256263","article-title":"Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages","volume":"28","author":"AT Reddy","year":"2014","journal-title":"FASEB J"},{"issue":"23","key":"ref25","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1038\/emboj.2011.393","article-title":"Ablation of Smurf2 reveals an inhibition in TGF-\u03b2 signaling through multiple mono-ubiquitination of Smad3","volume":"30","author":"LY Tang","year":"2011","journal-title":"EMBO J"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cells3040981","article-title":"Regulation of TGF-\u03b2 Superfamily Signaling by SMAD Mono-Ubiquitination","volume":"3","author":"F Xie","year":"2014","journal-title":"Cells"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1096\/fj.07-087627","article-title":"Fibroblast growth factor represses Smad-mediated myofibroblast activation in aortic valvular interstitial cells","volume":"22","author":"MC Cushing","year":"2008","journal-title":"FASEB J"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jcmm.13030","article-title":"FGF2 antagonizes aberrant TGF\u03b2 regulation of tropomyosin: role for posterior capsule opacity","volume":"21","author":"E Kubo","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1524-475X.2009.00511.x","article-title":"Basic fibroblast growth factor induces down-regulation of \u03b1-smooth muscle actin and reduction of myofibroblast areas in open skin wounds","volume":"17","author":"S Ishiguro","year":"2009","journal-title":"Wound Repair Regen"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jcp.20251","article-title":"Connective tissue growth factor causes persistent pro\u03b12(I) collagen gene expression induced by transforming growth factor-\u03b2 in a mouse fibrosis model","volume":"203","author":"S Chujo","year":"2005","journal-title":"J Cell Physiol"},{"issue":"136","key":"ref31","doi-asserted-by":"crossref","first-page":"136ra71","DOI":"10.1126\/scitranslmed.3003421","article-title":"A peptide derived from endostatin ameliorates organ fibrosis","volume":"4","author":"Y Yamaguchi","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7435","key":"ref32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature11774","article-title":"ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase","volume":"494","author":"H Zhou","year":"2013","journal-title":"Nature"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0186587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T06:15:38Z","timestamp":1659680138000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0186587"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0186587","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]}}}